It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Endemic mycoses such as histoplasmosis, coccidioidomycosis, blastomycosis, paracoccidioidomycosis, and talaromycosis are well-known causes of focal and systemic disease within specific geographic areas of known endemicity. However, over the past few decades, there have been increasingly frequent reports of infections due to endemic fungi in areas previously thought to be “non-endemic.” There are numerous potential reasons for this shift such as increased use of immune suppressive medications, improved diagnostic tests, increased disease recognition, and global factors such as migration, increased travel, and climate change. Regardless of the causes, it has become evident that our previous understanding of endemic regions for these fungal diseases needs to evolve. The epidemiology of the newly described Emergomyces is incomplete; our understanding of it continues to evolve. This review will focus on the evidence underlying the established areas of endemicity for these mycoses as well as new data and reports from medical literature that support the re-thinking these geographic boundaries. Updating the endemic fungi maps would inform clinical practice and global surveillance of these diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Kansas, Division of Infectious Diseases, Department of Internal Medicine, Kansas City, USA (GRID:grid.266515.3) (ISNI:0000 0001 2106 0692)
2 University of Kansas, Department of Internal Medicine, Kansas City, USA (GRID:grid.266515.3) (ISNI:0000 0001 2106 0692)
3 Centre Hospitalier de Cayenne, Centre d’Investigation Clinique Antilles-Guyane, Inserm 1424, Cayenne, French Guiana (GRID:grid.440366.3) (ISNI:0000 0004 0630 1955)
4 University of Manchester, Manchester Academic Health Science Centre, Faculty of Biology, Medicine, and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
5 Centers for Disease Control and Prevention, Geographic Research Analysis and Services Program, Division of Toxicology and Human Health Services, Atlanta, USA (GRID:grid.416738.f) (ISNI:0000 0001 2163 0069)
6 Mycotic Branch, Centers for Disease Control and Prevention, Atlanta, USA (GRID:grid.416738.f) (ISNI:0000 0001 2163 0069)
7 University of Alberta, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, Edmonton, Canada (GRID:grid.17089.37)